Find Funding Opportunities

Find Funding Opportunities

Subscribe to Find Funding OpportunitiesRSS
Returning 1200 results

Notice of Intent to Publish a Funding Opportunity Announcement for HEALthy Brain and Child Development Study

NOT
Friday, July 31, 2020
Heal
Wednesday, September 1, 2021
NOT-DA-20-069
Michelle Freund

Funding Opportunity Purpose

The purpose of this Notice is to alert the community that NIH plans to publish a set of Funding Opportunity Announcements (FOAs) as part of the Helping to End Addiction Long-termSM (HEAL) Initiative to support research project sites, a Data Coordinating Center, and a Consortium Administrative Core for the HEALthy Brain and Child Development (HBCD) Study. This Notice is being provided to allow potential applicants sufficient time to form meaningful collaborations and develop responsive applications. The primary objective of the HBCD Project is to conduct a large scale multi-site longitudinal study that can prospectively examine human brain, cognitive, behavioral, social, and emotional development beginning at birth and extending through middle childhood. The study will comprise a normative sample that represents the diversity of pregnant women in the US population, a cohort of women who have used opioids and other substances during pregnancy will also be recruited, and a comparison group from similar backgrounds/environments as the cohort of women who have used substances. The study is intended to create a well-characterized cohort of children in order to examine the developmental impact of pre/postnatal drug exposure and multiple other genetic and environmental factors that affect risk or resilience in various health and mental health domains. Anonymized data from this cohort will be made available to the broader research community during the course of the study to maximize their utility. The FOAs are expected to be published in Fall 2020 with an expected application due date in WINTER 2021. These FOAs will utilize the cooperative agreement (U) activity codes. Details of the planned FOAs are provided below. Research Initiative Details This Notice encourages investigators with expertise and insights in neurodevelopment to consider applying for these new FOAs. This project is expected to be a collaboration between researchers having wide ranging expertise. This includes expertise in areas such as: neuroimaging, neurodevelopment, cognitive and behavioral science, environmental science, gene/environment interactions, substance use, mental health, family dynamics, bioethics, data management and biostatistics; as well as recruitment and retention of vulnerable populations in long term studies. The goal of the HBCD Project is to collect data in multiple domains to provide knowledge about the multiplicity of factors that affect a child’s health, brain, and behavioral development, an essential first step toward designing policies and interventions that promote well-being and resilience in all children. Below are some of the overarching research objectives, which are inherently interdependent and mutually informative: What does normative brain development look like from birth through childhood, and how do various biological and environmental factors affect these development trajectories? How do genetic factors interact with environmental factors to influence neurodevelopmental and cognitive development? How does early life exposure to substances (alone or in combination) and/or adverse or protective environmental circumstances affect the developmental trajectories of children? Are there key developmental windows during which the impact of adverse environmental exposures (e.g., opioids, stress, COVID-19) influence later neurodevelopmental outcomes? Are there key developmental windows during which ameliorating influences (e.g, SUD treatment; social/economic support) are protective against the potential neurodevelopmental insults of early adverse exposures? It is expected that investigators, upon funding, will work together with federal staff at NIH Institutes, Centers and Offices to achieve project goals.

Notice of Intent to Publish a Funding Opportunity Announcement for NIH Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program: FIRST Cohort (U54 Clinical Trial Not Allowed)

NOT
Wednesday, July 29, 2020
Monday, November 9, 2020
NOT-RM-20-023

Funding Opportunity Purpose

The purpose of this Notice is to inform the research community that the NIH Common Fund, along with its partner NIH Institutes, Centers, and Offices, is planning to issue a funding opportunity announcement (FOA) to support the NIH Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program: FIRST Cohort. We expect to re-release this funding opportunity for a total of 3 rounds. This Notice is being provided to allow potential applicants sufficient time to develop meaningful plans for robust applications to this opportunity. The FOA is expected to be published in Fall, 2020 with an expected application due date in November 2020. This FOA will utilize the U54 activity code. Details of the planned FOA are provided below. Research Initiative Details The NIH supported biomedical research workforce is more likely to thrive in environments that support equity, diversity, and social justice. The overall program objective of Faculty Institutional Recruitment for Sustainable Transformation (FIRST) is to create cultures of inclusive excellence at NIH-funded institutions by implementing a set of well-integrated, evidence-based strategies and evaluating their impact on prespecified metrics of institutional culture, inclusion, and diversity. Inclusive excellence is a philosophical approach to higher education administration and processes that means attending to both the demographic diversity of faculty/students and the need for developing climates and cultures in institutions so that all have a chance to succeed in STEMM (National Academies of Sciences, Engineering, and Medicine 2019. The Science of Effective Mentorship in STEMM (STEMM stands for Science, Technology, Engineering, Mathematics, and Medicine)). The FIRST Program will provide one funding mechanism with opportunities for Highly Resourced Institutions (HRI) and Limited-Resourced Institutions (LRI) to apply independently or in a partnership arrangement to develop and implement faculty cohort models for the simultaneous hiring of a diverse group of research faculty. LRIs are institutions offering doctorate degrees in the health professions or in a health-related science and have a historical and current commitment to educating underrepresented students, and for institutions that deliver health care services, providing clinical services to medically underserved communities. They must also have received less than $50 million average in annual NIH funds within the three years prior to the time of application (applies Research Centers in Minority Institutions criteria ). Any individual who is competitive for a tenure track faculty position and who has demonstrated a strong commitment to promoting diversity and inclusive excellence is eligible for FIRST faculty positions. Faculty candidates will be required to submit a statement describing their commitment to promoting diversity and inclusive excellence. Institutions will decide how to evaluate this commitment, but some examples include the area of a candidate’s research program, active participation in diversity efforts, mentoring individuals from underrepresented backgrounds, volunteer activities in the community, etc. Selection for the program should be competitive and inclusion in the FIRST cohort will be viewed as a prestigious recognition of outstanding accomplishments both in scientific research and in promoting diversity and inclusive excellence. The program will support activities for faculty to receive multilevel mentoring, sponsorship, professional and research development embedded within institutions that are actively implementing integrated, systems-level approaches for sustainable culture change. FIRST applicant institutions are encouraged to enhance the diversity of the FIRST faculty cohort by including candidates from groups identified as underrepresented in the biomedical, clinical, behavioral, and social sciences, some of which are described in NOT-OD-20-031, such as racial and ethnic minorities, those from disadvantaged backgrounds, individuals with disabilities, and women at the faculty level. Institutional cohorts may be comprised of small clusters of scientists within several scientific areas, such as neuroscience, cardiovascular disease, cancer, minority health and health disparities, behavioral, social, or other research areas within the NIH mission either at one institution or at partnering institutions. FIRST Cohort programs will operationalize through three cores—Administrative, Faculty Development, and Evaluation cores. The overall goals and specific measurable objectives that the program expects to accomplish are in the areas of: sustainable institutional culture change; promote inclusive excellence by hiring a diverse cohort of new faculty; faculty development, mentoring, sponsorship, and promotion. Each institution will be responsible for evaluating its own FIRST program. The CEC will be responsible for evaluating the attainment of FIRST goals consortium wide.

Notice of Intent to Publish a Funding Opportunity Announcement for NIH Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program: FIRST Coordination and Evaluation Center (U54 Clinical Trial Not Allowed)

NOT
Wednesday, July 29, 2020
Monday, November 9, 2020
NOT-RM-20-022
Rina Das

Funding Opportunity Purpose

The purpose of this Notice is to inform the research community that the NIH Common Fund, along with its partner NIH Institutes, Centers, and Offices, is planning to issue a funding opportunity announcement (FOA) to support the NIH Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program: FIRST Coordination and Evaluation Center. This will be an open competition. This Notice is being provided to allow potential applicants sufficient time to develop meaningful plans for robust applications to this opportunity. The FOA is expected to be published in Fall, 2020 with an expected application due date in November 2020. This FOA will utilize the U54 activity code. Details of the planned FOA are provided below. Research Initiative Details The NIH supported biomedical research workforce is more likely to thrive in environments that support equity, diversity, and social justice. The overall program objective of Faculty Institutional Recruitment for Sustainable Transformation (FIRST) is to create cultures of inclusive excellence at NIH-funded institutions by implementing a set of well-integrated, evidence-based strategies and evaluating their impact on prespecified metrics of institutional culture, inclusion, and diversity. Inclusive excellence is a philosophical approach to higher education administration and processes that means attending to both the demographic diversity of faculty/students and the need for developing climates and cultures in institutions so that all have a chance to succeed in STEMM (National Academies of Sciences, Engineering, and Medicine 2019. The Science of Effective Mentorship in STEMM). STEMM stands for Science, Technology, Engineering, Mathematics, and Medicine. The purpose of the FIRST Coordination and Evaluation Center (CEC) is to coordinate and facilitate consortium-wide activities, lead the development of evaluation strategies, instruments, metrics, common data elements, and to assess the impact and outcomes of the FIRST initiative overall. The FIRST CEC will work collaboratively with awardees to: (1) identify fundamental attributes of promoting inclusive excellence by successful faculty cluster and cohort hiring, development, and retention efforts; (2) identify metrics for site-specific sustainable institutional culture change goal; (3) coordinate data acquisition across sites and harmonize basic measures to be used; (4) evaluate the impact of approaches implemented by each site on the attainment of inclusive excellence, including diversity and equity measures; and (5) disseminate evidence-based practices implemented by each site and lessons learned to transform and adapt models nationwide. CEC functions will be operationalized through four cores: Administrative, Evaluation, Data Coordination, and Communication and Dissemination Cores. The FIRST CEC will be responsible for evaluating the attainment of FIRST goals consortium wide, rather than evaluating individual FIRST Cohort awardees. The overall goals and specific measurable objectives that the program expects to accomplish are in the areas of: (1) sustainable institutional culture change; (2) promote institutional inclusive excellence by hiring a diverse cohort of new faculty; and (3) faculty development, mentoring, sponsorship, and promotion.

Notice of Change to Key Dates for PAR-18-657 "Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 Clinical Trial Optional)".

NOT
Friday, July 10, 2020
Sunday, January 1, 2023
NOT-NS-20-086

Funding Opportunity Purpose

Notice Change Key Dates PAR-18-657 Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional)". Notice Number: NOT-NS-20-086 Key Dates Release Date: July 10, 2020 Related Announcements PAR-18-657 - Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) National Eye Institute NEI) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) Purpose purpose this notice to inform interested applicants a change the Key Dates PAR-18-657 "Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional)". September 9, 2020 receipt date been changed October 8, 2020. Changes show bold italics below. Currently Reads: Part 1. Overview Information Key Dates Application Due Date(s) September 11, 2018; September 10, 2019; September 9, 2020, 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Expiration Date September 10, 2020 Modified Read: Part 1. Overview Information Key Dates Application Due Date(s) September 11, 2018; September 10, 2019; October 8, 2020, 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Expiration Date October 9, 2020 other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: David A. Jett, Ph.D. National Institute Neurological Disorder Stroke NINDS) Telephone: 301-496-6035 Email: jettd@ninds.nih.gov

Notice of Change to Key Dates for PAR-19-039 "Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead Compounds (U01 Clinical Trial Not Allowed)"

NOT
Friday, July 10, 2020
Sunday, January 1, 2023
NOT-NS-20-087

Funding Opportunity Purpose

Notice Change Key Dates PAR-19-039 Countermeasures Against Chemical Threats CounterACT): Identification Therapeutic Lead Compounds U01 Clinical Trial Allowed)" Notice Number: NOT-NS-20-087 Key Dates Release Date: July 10, 2020 Related Announcements PAR-19-039 - Countermeasures Against Chemical Threats CounterACT): Identification Therapeutic Lead Compounds U01 Clinical Trial Allowed) Issued National Institute Neurological Disorders Stroke NINDS) National Eye Institute NEI) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) Purpose purpose this notice to inform interested applicants a change the Key Dates PAR-19-039 "Countermeasures Against Chemical Threats CounterACT): Identification Therapeutic Lead Compounds U01 Clinical Trial Allowed)". September 9, 2020 receipt date been changed October 8, 2020. Changes show bold italics below. Currently Reads: Part 1. Overview Information Key Dates Application Due Date(s) September 10, 2019; September 9, 2020; September 14, 2021, 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Modified Read: Part 1. Overview Information Key Dates Application Due Date(s) September 10, 2019; October 8, 2020; September 14, 2021, 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: David A. Jett, Ph.D. National Institute Neurological Disorder Stroke NINDS) Telephone: 301-496-6035  Email: jettd@ninds.nih.gov

Notice of Change to Key Dates for PAR-19-040 "Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01 Clinical Trial Optional)"

NOT
Friday, July 10, 2020
Sunday, January 1, 2023
NOT-NS-20-088

Funding Opportunity Purpose

Notice Change Key Dates PAR-19-040 Countermeasures Against Chemical Threats CounterACT): Optimization Therapeutic Lead Compounds U01 Clinical Trial Optional)" Notice Number: NOT-NS-20-088 Key Dates Release Date: July 10, 2020 Related Announcements PAR-19-040 - Countermeasures Against Chemical Threats CounterACT): Optimization Therapeutic Lead Compounds U01 Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) National Eye Institute NEI) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) Purpose purpose this notice to inform interested applicants a change the Key Dates PAR-19-040 "Countermeasures Against Chemical Threats CounterACT): Optimization Therapeutic Lead Compounds U01 Clinical Trial Optional)". September 9, 2020 receipt date been changed October 8, 2020. Changes show bold italics below. Currently Reads: Part 1. Overview Information Key Dates Application Due Date(s) September 10, 2019; September 9, 2020; September 14, 2021, 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Modified Read: Part 1. Overview Information Key Dates Application Due Date(s) September 10, 2019; October 8, 2020; September 14, 2021, 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: David A. Jett, Ph.D. National Institute Neurological Disorder Stroke NINDS) Telephone: 301-496-6035  Email: jettd@ninds.nih.gov

Notice of New Budget Limitation for PAR-18-657 "Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 Clinical Trial Optional)"

NOT
Wednesday, July 8, 2020
Sunday, January 1, 2023
NOT-NS-20-085

Funding Opportunity Purpose

Notice New Budget Limitation PAR-18-657 Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional)" Notice Number: NOT-NS-20-085 Key Dates Release Date: July 8, 2020 Related Announcements PAR-18-657 - Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional) NOT-NS-18-072 - Rescinded - Notice New Budget Limitation PAR-18-657 Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) National Eye Institute NEI) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) Purpose purpose this notice to inform applicants a change the Application Budgets PAR-18-657 "Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional)". notice updates, supercedes replaces previous notice, NOT-NS-18-072 "Notice New Budget Limitation PAR-18-657 Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional)". Specifically, application budgets be reduced 2 million direct costs per yearto 1.75 million direct costs per year. notice be effective the October 8, 2020 receipt date. Change shown below bold italics. Currently Reads: Section II. Award Information Award Budget Application budgets not exceed 2.0 million direct costs per year. applications not need request maximum budget the size duration the awards vary because nature scope research programs vary. Modified Read: Section II. Award Information Award Budget Application budgets not exceed 1.75 million direct costs per year. applications not need request maximum budget the size duration the awards vary because nature scope research programs vary. other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: David A. Jett, Ph.D. National Institute Neurological Disorder Stroke NINDS) Telephone: 301-496-6035 Email:jettd@ninds.nih.gov

Notice of Change to Key Dates for RFA-NS-20-030 "Research Program Award (R35 Clinical Trial Optional)"

NOT
Tuesday, July 7, 2020
Sunday, January 1, 2023
NOT-NS-20-092

Funding Opportunity Purpose

Notice Change Key Dates RFA-NS-20-030 Research Program Award R35 Clinical Trial Optional)" Notice Number: NOT-NS-20-092 Key Dates Release Date: July 7, 2020 Related Announcements RFA-NS-20-030 - Research Program Award R35 Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to inform interested applicants a change the Key Dates RFA-NS-20-030 "Research Program Award R35 Clinical Trial Optional)". July 31, 2020 receipt date been moved August 14, 2020. Changes shown below bold italics. Currently Reads: Part 1. Overview Information Key Dates Letter Intent Due Date(s) July 1, 2020 Application Due Date(s) July 31, 2020 late applications be accepted this Funding Opportunity Announcement. applications due 5:00 PM local time applicant organization. Alltypes non-AIDS applicationsallowed this funding opportunity announcement due the listed date(s). Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Expiration Date August 01, 2020 Modified Read: Part 1. Overview Information Key Dates Letter Intent Due Date(s) July 21, 2020 Application Due Date(s) August 14, 2020 late applications be accepted this Funding Opportunity Announcement. applications due 5:00 PM local time applicant organization. Alltypes non-AIDS applicationsallowed this funding opportunity announcement due the listed date(s). Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Expiration Date August 15, 2020 other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Anna Taylor, Ph.D.National Institute Neurological Disorders Stroke NINDS)Telephone: 301-827-3565Email:anna.taylor@nih.gov

Notice of Clarification to Application Types Allowed PAR-20-111 "Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)"

NOT
Tuesday, July 7, 2020
Sunday, January 1, 2023
NOT-NS-20-091

Funding Opportunity Purpose

Notice Clarification Application Types Allowed PAR-20-111 Blueprint Neurotherapeutics Network BPN): Small Molecule Drug Discovery Development Disorders the Nervous System U44 Clinical Trial Optional)" Notice Number: NOT-NS-20-091 Key Dates Release Date: July 7, 2020 Related Announcements PAR-20-111 - Blueprint Neurotherapeutics Network BPN): Small Molecule Drug Discovery Development Disorders the Nervous System U44 Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to clarify Application Types Allowed PAR-20-111 "Blueprint Neurotherapeutics Network BPN): Small Molecule Drug Discovery Development Disorders the Nervous System U44 Clinical Trial Optional). Activity Code section Part 1. Overview Information) been modified remove following text "U44Small Business Innovation Research SBIR) Cooperative Agreements - Phase II". text being removed be consistent Section II. Award Information stating only New Fast-Track) applications be accepted response this Funding Opportunity Announcement FOA). change be effective the August 11, 2020 receipt date subsequent due dates.Changes the FOA shown below. Currently Reads: Part 1. Overview Information Activity Code U44Small Business Innovation Research SBIR) Cooperative Agreements - Phase II U44Small Business Innovation Research SBIR) Cooperative "Agreement – Fast Track" Modified Read: Part 1. Overview Information Activity Code U44Small Business Innovation Research SBIR) Cooperative "Agreement – Fast Track" other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Charles Cywin, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1779 Email:charles.cywin@nih.gov

Notice of Participation in PA-18-358, "NINDS Exploratory Neuroscience Research Grant (R21- Clinical Trial Optional)"

NOT
Tuesday, July 7, 2020
Sunday, January 1, 2023
NOT-MH-20-034

Funding Opportunity Purpose

Notice Participation PA-18-358, NINDS Exploratory Neuroscience Research Grant R21- Clinical Trial Optional)" Notice Number: NOT-MH-20-034 Key Dates Release Date: July 7, 2020 Related Announcements PA-18-358,NINDS Exploratory Neuroscience Research Grant R21- Clinical Trial Optional) Issued National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) Purpose purpose this Notice to inform potential applicants NIMH's participation, effective immediately, PA-18-358, " NINDS Exploratory Neuroscience Research Grant R21- Clinical Trial Optional)" the next receipt date October 16, 2020. following sections PA-18-358 been updated reflect participation NIMH this Notice: Part 1. Overview Information Components Participating Organizations National Institute Neurological Disorders Stroke NINDS) National Institute Mental Health NIMH) Section Funding Opportunity Description Areas scientific interest the NIMH reflect Neuroscience areas priority detailed the NIMH Strategic Plan found within following divisions offices. Division Neuroscience Basic Behavioral Science DNBBS) supports research programs basic neuroscience, genetics, resource technology development, drug discovery. Examples priorities include are limited these topics: Discover novel mechanisms nervous system development across genes, proteins, cells circuitry) signaling properties underlie emergence cognition, emotion, social behavior. Develop use innovative strategies, including genome-wide comparative approaches, discover genes gene regulatory mechanisms underlying brain functions includingcognition, emotion, social behavior. Discover cellular molecular mechanisms whereby hormones immune molecules modulate signaling brain circuits relevant emotion regulation, cognition, social behavior. Develop empirically evaluate computational theoretical models address plasticity brain circuits during development impacting cognitive, affective, social behaviors. Research elucidate genomic risk factors underlie mental disorders. Division Translational Research DTR) supports research translates knowledge basic science discover etiology, pathophysiology, trajectory mental disorders develops effective interventions children adults. Examples priorities include are limited these topics: Delineate specific neural circuits contributing one more major mental disorders subtypes mental disorders. Identify mechanisms e.g., biological, behavioral, environmental) confer vulnerability psychiatric illnesses. Discover novel targets future therapeutic intervention identifying causal relationships between neural circuits symptom expression. Delineate neurobehavioral mechanisms responsible the development psychopathology, including critical sensitive periods brain development the effects sex, behavior, experience the brain. Assess mechanisms action efficacious interventions the brain bench, pre-clinical context, computational models. Division AIDS Research DAR) supports research basic clinical neuroscience HIV infection. Examples priorities include are limited these topics: Understand decipher a molecular level, HIV associated neuroimmune dysregulation impacts neuronal receptors, neuroendocrine milieu, neurotransmitters synaptic plasticity the context HIV anti-retroviral therapy. Pre-clinical research studies target neuroimmune dysregulation, blood brain barrier disruption altered neuronal circuitry individuals living HIV to decipher potential CNS toxicities associated anti-retroviral therapy other emergent treatments HIV cure. Support use state-of-the-art epi)genetic approaches identify validate viral host genetic factors influence pathophysiology manifestations HIV-induced CNS dysfunction. Define characterize HIV persistence the CNS the context suppressive highly active antiretroviral therapy foster translational research enable eradication HIV the brain. Office Technology Development Coordination OTDC): Supports basic applied research related the development scientific tools, technologies, approaches related brain behavioral research. Any Clinical Trial research submitted NIMH under R21 mechanism must follow guidance noted NIMH NOT-MH-19-006. is, NIMH supports hypothesis-driven mechanistic clinical trial studies basic and/or translational discovery research health human subjects in pathobiology, pathophysiology psychopathology mental disorders in HIV infection the central nervous system CNS). goal to address basic questions to interrogate concept biology, behavior, pathophysiology will provide insight to understanding mental health mental disorders. https://www.nimh.nih.gov/funding/opportunities-announcements/clinical-trials-foas/index.shtml. Inquiries Please direct inquiries to: Susan Koester, Ph.D.National Institute Mental Health NIMH)Telephone:301-443-3563Email: koesters@mail.nih.gov

Pages